Two pneumococcal polysaccharide, or PPSV23, vaccines are administered to adults with such conditions as asthma, kidney disease, heart disease and lung disease, including potential candidates for lung disease, if they are between the ages of 19 and 64, according to WebMD. The vaccines are given in five-year increments.
The pneumococcal conjugate, or PCV13, vaccine is given to adults 19 and older who have asplenia, sickle cell disease, cochlear implants or cerebrospinal fluid leaks, as stated by WebMD. Senior citizens above the age of 65 should receive both the PPSV23 vaccine and the PCV13 vaccine, with the PCV13 administered first followed by the PPSV23 in eight weeks.
The pneumococcal vaccine prevents the Streptococcus pneumoniae bacteria from causing infections that affect the blood, brain and lungs negatively, infections that include pneumonia, WebMD explains. The PPSV23 vaccine protects against 23 strains of the bacteria.